MUNICH - September 5, 2022 - (Newswire.com)

neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best practice, is pleased to announce the signing of a cooperation and agency agreement ("Agreements") for its Digital Therapy Platform (DTP) and clinics rollout throughout the Middle East region, the Republic of Ireland and Northern Ireland.

Under the Agreements, neurocare's cooperation partner Live a Better Life Ltd (LABL) will bring the Company's Digital Therapy Platform (DTP) and clinics to the Middle East and all of Ireland. LABL is a business co-founded by successful Dubai-based healthcare investor and entrepreneur Sean Ewing who founded and recently sold Salma Critical Care Hospital to the Abu Dhabi Government and Alcazar Capital Limited, a Dubai-based investment firm with numerous successful healthcare ventures in the UAE and a strong value creation track record of developing companies into market leaders.

In addition to rolling out various clinical treatment facilities throughout the regions of the cooperation, LABL will act as distributors of the Company's transcranial magnetic stimulation (TMS) systems and neurofeedback devices. The objective of the cooperation is to assist clinicians address significant waiting lists and improve clinician capacity whilst improving clinical outcomes for patients. LABL will make an upfront investment into neurocare group AG as well as ongoing additional investments into buying and building local clinics to accelerate the growth of neurocare's DTP for third party clinics.

"We are very pleased to announce the cooperation with Live a Better Life, a strong partner with deep local industry experience," says Tom Mechtersheimer, founder and CEO of neurocare. "The partnership allows us to expand neurocare's geographic footprint into new regions by providing our technologies and services expressed in neurocare's scalable digital therapy platform, while following our growth strategy focusing our own resources on our key markets in the US, mainland Europe and Australia. The implementation of our DTP in LABL's clinics serves as a milestone proof point for our DTP."

"We are proud to be able to provide neurocare's personalized approach to mental healthcare that empowers clinicians to deliver the best possible and most sustainable outcome for patients," says Anshul Garg, Healthcare Executive at Life a Better Life Ltd. "neurocare's digital therapy platform has the potential to make more effective and sustainable mental healthcare accessible in the Middle East and all of Ireland while enhancing the clinician's efficiency and improving patient results."

About neurocare group AG:

neurocare is innovating mental health and performance. We offer the first digital therapy platform (DTP) empowering clinicians to deliver best practice. Our integrated and personalized therapy approach is based on a strong clinical science background with over 20 years of research and technology development. Our business is driven by two strong growth channels: building our own clinics and providing our unique DTP to third parties. We currently treat about 2,800 patients annually in our own clinics and serve many third party practices with our personalized therapy approach, our technologies and related training / onboarding. www.neurocaregroup.com

Pamela Keck
neurocare group AG
[email protected]

Press Release Service by Newswire.com

Original Source: neurocare group AG expands international footprint with cooperation in the Middle East, the Republic of Ireland and Northern Ireland

How Big Tobacco transformed into a vaping public health crisis headed by America's youth.

SAN FRANCISCO - September 2, 2022 - (Newswire.com)

Jennifer Banmiller, pro consumer advocate and owner of publishing company Periscope Group, and Dr. Tsai, renowned thoracic surgeon, have released an alarming and awakening book on the crisis that is vaping. What they uncovered was a horrific public health nightmare for American youth. 

The purpose of this book is to expose this industry for what it is: an unconscionable business that makes billions by selling addictive and potentially fatal products to impressionable youngsters.

The authors hope to shine a spotlight on their insidious plan to hide the dangers of vaping from unsuspecting youth and the "irredeemably evil" fact documented in this book showing the industry preying on children as young as 8 years old by funding summer camps, paying community churches to distribute theorem material, and targeting veterans groups and other vulnerable populations. Targeting young people thus becomes an annuity for the tobacco industry, at a horrible cost to youth.

What began as a master's thesis for two graduate students ended up as the impetus for one of the most treacherous tricks ever played on the American people and particularly on teens and young adults. Insisting that their product was a smoking cessation product, vaping companies, backed by Big Tobacco companies who saw a way back into the youth smoking market share, created the most enticing and cool E-cigarette products imaginable. The marketing was purposeful. First, through packaging, using high-tech, teen-cool, easily hidden devices called vape pens, reminiscent of Apple products, both colorful and sleek.

No scientific testing was done to protect the public prior to the release of these products. And in the face of all this injury and death, E-cig companies only made minor changes to their products and methods when pressured, and even now, as the CDC declares a national vaping epidemic and every state in the U.S. has enacted laws to protect citizens, and over 60 people have died and thousands are permanently injured, these companies continue to profit.

In Statutory Vape, readers will discover how easy it actually was to perpetrate such a dangerous product, about how a simple design supposedly created for one use became a public health hazard once dollars were the prize, about the lack of scientific testing prior to the release of vapes, and about what is being done now so this never happens again.

To learn more about this national crisis and buy the book, please visit statutoryvape.com or periscopegroup.com

For more information on Jennifer Banmiller, visit Jennifer Stanich Banmiller or email [email protected]

Podcast with Dr. Tsai

Related Files
Scannable Document on Sep 1, 2022 at 1_41_13 PM copy.png



Press Release Service by Newswire.com

Original Source: Jennifer Banmiller and Dr Tsai Release Groundbreaking Book: Statutory Vape

Nasal Swab Validation for Monkeypox

SAN FRANCISCO - September 1, 2022 - (Newswire.com)

Virus Geeks, a leading developer in biotech and life-changing innovations, announced today the first Nasal swab validated for Monkeypox, Covid-19, and Influenza A&B all in one testing and will be available through the company's laboratory services. This innovation changes the dynamics of testing for the Monkeypox virus by reducing the risk of infection for the public and most medical staff at the point of test. With a growing number of MPXV cases, it has become necessary for diagnostic laboratories to quickly, efficiently, and accurately implement a way to identify patients infected with the virus. Virus Geeks affiliated lab validated ANDiS Monkeypox virus nucleic acid detection kit for the purpose of the qualitative detection of the Monkeypox virus on the Applied Biosystems™ QuantStudio 5 Real-Time PCR instrument. The ANDiS Monkeypox virus nucleic acid detection kit is a molecular test that aids in the diagnosis of the Monkeypox virus and is based on widely used nucleic acid amplification technology. As the flu season approaches, Virus Geeks continues to stay ahead of the curve by making testing seamless with this solution of a single swab product. The product contains oligonucleotide primers and fluorescent dye-labeled probes and control material used in RT.

About Virus Geeks

Virus Geeks is a data-driven Bio-Health Technology Company that develops health-centric initiatives to improve the quality of life through strategic partnerships across healthcare & biotechnology sectors. They help large populations gain access to molecular diagnostic testing and provide organizations with the technology to efficiently manage data.

Virus Geeks is a community-first company that prioritizes the safety and well-being of individuals by making testing easy and stress-free. Thanks to the CEO Frank Lee who is committed to life-changing medicine and technology, Virus Geeks will continue to be committed to the development of adequate testing kits that truly benefit the public with all our strength from a global perspective while promoting proper business activities based on awareness of corporate social responsibility In compliance with relevant laws and in accordance with high ethical standards. The Company strive for a continuous positive impact in the community by listening and collaborating with local organizations to spread awareness on issues concerning the health of residents. 

To learn more about this and innovative solutions from Virus Geeks, visit the website at www.virusgeeks.com or contact customer service at 1-800-731-8815. For organization or corporate sales, email: [email protected].

Press Release Service by Newswire.com

Original Source: Virus Geeks, a Biotechnology Company, Becomes the First to Validate a Nasal Swab for Monkeypox, Covid-19, Influenza A&B All in One Swab

Compass Health Center is launching an Adolescent OCD and Complex Anxiety Disorder Program at its Oak Brook location

OAK BROOK, Ill. - September 1, 2022 - (Newswire.com)

In response to the growing need for targeted clinical services to treat Obsessive Compulsive Disorder (OCD) and other anxiety disorders in adolescents, Compass Health Center is launching its Adolescent OCD and Complex Anxiety Disorder Partial Hospitalization and Intensive Outpatient (PHP/IOP) program at its Oak Brook location on Sept. 6, 2022. The goal of this new program is to provide specialized, evidence-based treatment for OCD and anxiety disorders among adolescents ages 13-18 in the Western Suburbs.  

"Since settling into the community over the past year, we've seen more and more adolescents and their families in need of specialized services to treat OCD & anxiety disorders including but not limited to social anxiety, school anxiety, and school refusal," said Katrina Shannon, LMFT, Director of Adolescent Program, Compass Health Center - Oak Brook. "We have seen the positive impact and outcomes of our adolescent OCD programming at both our Northbrook and Chicago locations and are eager to provide this effective and engaging treatment in Oak Brook." 

OCD is a mental health diagnosis in which people experience recurring thoughts, ideas, and sensations (obsessions) that make them feel a strong urge to repeat specific actions or behaviors (compulsions). If not properly managed, these actions and behaviors can significantly interfere with an individual's ability to function in their daily life. Complex Anxiety refers to those conditions/disorders that research shows best respond to Exposure and Response Prevention (ERP) as a treatment modality. These conditions include OCD, Social Anxiety, Panic Disorder, Separation Anxiety Disorders, Phobias, and Illness Anxiety Disorder. 

OCD and anxiety disorders cause problems, not because they make people feel anxious, but because of how we as humans tend to respond to anxiety, by avoiding what causes the anxiety. This avoidance ends up causing more problems than it solves and results in deteriorating relationships, skipping school, academic difficulties, and family conflict. ERP systematically decreases the avoidance triggered by anxiety and prompts the patients to build more meaning and purpose in their lives, even if it requires them to feel anxious in the process. 

For those with OCD and anxiety disorders, the effects of the pandemic worsened symptoms, Time Magazine reports. "New research shows that OCD symptoms have gotten more severe for many people during the pandemic, and new diagnoses have increased." In addition, a BMC Psychiatry study in 2020 found that nearly 45% of young people ages 7 to 21 experienced a worsening of overall OCD symptoms within the first pandemic year. 

"With the loss of their routines and their social lives, many adolescents expectedly struggled with their mental health during the pandemic. For teens with OCD or anxiety diagnoses, specialized treatment including an exposure plan is key to positive treatment outcomes," said Meg Hoffman, LCSW, Associate Director of Adolescent OCD and Complex Anxiety Program, Compass Health Center - Northbrook. "Adolescents in our OCD & Complex Anxiety Program learn evidence-based coping skills, participate in exposure and process groups, and engage in individual exposure therapy. Each patient works with a treatment team, including a psychiatrist or psychiatric nurse practitioner, an individual therapist, a family therapist, and, during the school year, an education specialist toward their unique and mutually-established treatment plan goals." 

Compass's Adolescent OCD & Complex Anxiety Program (PHP/IOP) provides therapy modalities rooted in daily ERP as well as Acceptance and Commitment Therapy (ACT), Cognitive Behavioral Therapy (CBT), Dialectical Behavior Therapy (DBT), and habit reversal training. Adolescents attend group therapy sessions and meet daily with an exposure therapist to address symptoms and triggers leading to avoidance and compulsions. Through these evidence-based therapies, adolescents learn to tolerate distressing thoughts and physical sensations so that they can more fully and meaningfully engage in their daily lives. Programming is now available at all Compass onsite locations. Visit Compass Health Center's website or call now for an intake.  

Press Release Service by Newswire.com

Original Source: New Adolescent Obsessive-Compulsive Disorder Program Addresses an Increased Need for Specialized Exposure and Response Prevention Therapy in Chicago Suburbs

AUBURN, Ala. - September 1, 2022 - (Newswire.com)

SiO2 Materials Science today announced the Board of Directors has appointed Yves Steffen as CEO effective Aug. 1, 2022. 

Yves brings very valuable customer experience along with high personal values and leadership skills to take the company to the next level. Yves Steffen is a graduate of FHBB and has more than 20 years of experience in the pharmaceutical industry in various positions. His career started at Cilag AG (a Johnson&Johnson company) as a Project Engineer, where he was responsible for the installation, qualification and validation of aseptic filling, visual inspection and packaging lines. In 2006, he moved to Novartis, where he was initially responsible for technical services at the manufacturing site in Switzerland and then took on a role responsible for product transfers and launches of biopharmaceuticals. In 2014, he established a device and packaging commercialization group at Novartis, first for biosimilars and later for biologics. Yves then moved to SHL Medical AG as Global Director of Sustainability, where he was responsible for all sustainability initiatives of the company. In October 2021, he joined SiO2 to build the company's European presence and develop the mid-term strategic roadmap.

Robert Abrams, Chairman of the SiO2 Board, said, "In recent years, SiO2 has successfully completed the development of a revolutionary technology for the life science industry. In the coming years, Yves' mission will be to make SiO2 a leading sustainable company in the primary packaging market by delivering best-in-class products and making the company an employer of choice with a heightened focus on customer-centricity. We wish Yves the best of success in his new role." 

"I'm incredibly excited to lead SiO2 through the next phase of commercialization and growth," said Mr. Steffen, "The drug packaging industry has been slow to innovate for the past 100 years and there is a tremendous need in the market for a next-generation packaging solution that can support the next generation of drugs being developed. SiO2 is perfectly positioned to capture this demand and I look forward to working alongside the team as we expand our customer base."

For more information on SIO2, visit www.SiO2MS.com. 

About SiO2 Materials Science: 

SiO2 Materials Science is an advanced materials science corporation introducing breakthrough disruptive technology serving the biopharma, molecular diagnostic, and consumer healthcare industries. The company is located in Auburn, Alabama. The company has deep partnerships with leading professors at the foremost research universities, such as the University of California - Santa Barbara, the University of Chicago, and MIT. For more information, visit www.sio2ms.com.

Media contact: 
[email protected]

Press Release Service by Newswire.com

Original Source: SiO2 Materials Science Names Yves Steffen as Chief Executive Officer

ZUG, Switzerland - September 1, 2022 - (Newswire.com)

Today DJIB launched the first ever end-to-end encrypted, enterprise grade decentralised data storage drive with embedded multi chain non-fungible token functionality. It enables the widespread adoption of NFTs in business applications.

Cloud data storage is dominated by services such as Amazon AWS, Google Cloud and Microsoft Azure. However, in the age of blockchains, users find traditional storage limiting as it is centralised in the hands of individual corporations. User data can be potentially accessed without their knowledge by employees of such providers. The currently missing ability to save objects as NFTs will be increasingly required in business applications.

This is why, while being AWS S3 compatible and blazingly fast, the DJIB data storage drive for the first time addresses all of these concerns by being end-to-end encrypted, censorship resistant, and with built-in NFT functionality. It reimagines the concept of NFTs, treating them as a new type of file format, whereby users can "Save as NFT" any file stored on the drive, thus demystifying the creation of NFTs. Files can be up to 5TB large, which removes currently existing technical constraints. Users can either attach custom business logic to their NFTs, or use pre-defined templates from a library without knowing how to code. For example, a musician can publish a song with pre-defined licensing rights, or a pharmaceutical company can allow patients to share and profit from their medical data with very granular permissions and usage rights - all without the need of any intermediaries or use of specialist software. Any asset can now be tokenised. Any financial director can issue share certificates in NFT format.

Such NFTs are immediately interoperable with all the blockchains with which DJIB has a connector. It started from Solana, Ethereum and BSC, but will soon cover all key networks. DJIB is already working on connectors with teams from major blockchains, starting with those that are enterprise focused and see this as an opportunity to foster the development of applications within their ecosystems.

Moe Sayadi, DJIB CEO whose background is of a solutions architect at Microsoft and Avaloq, says: "Making our decentralised drive available to enterprise customers and removing the mystery behind the creation of NFTs opens an unimaginable trove of opportunities. It puts a powerful tool into the hands of non-technical domain experts. They can focus on the business logic attached to any document and potentially physical item, and move entire business processes to the cloud. This enables Object Oriented Business Process Management and many other exciting innovations which are in our pipeline and will be announced soon. We are discussing with corporate CTOs some very interesting use cases and I can confidently say that NFT evolution has finally passed the apes stage."

Contact: Max Atanassov [email protected] +41-79-566-3797

Press Release Service by Newswire.com

Original Source: DJIB Launches First Ever Enterprise Grade Decentralised Data Storage Drive